Gilead HCV sales short of expectations in 1Q16

Gilead Sciences Inc. (NASDAQ:GILD) slipped $5.35 to $91.65 in early after-hours trading Thursday after it reported 1Q16 earnings that missed analysts' estimates, in part due to lower than

Read the full 281 word article

User Sign In